About promis neurosciences inc - PMN
ProMIS Neurosciences, Inc. engages in the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases. It focuses on the progression of Alzheimer's disease, amyotrophic lateral sclerosis, and Parkinson's disease. The company was founded by Neil Cashman and Vigen Nazarian on January 23, 2004 and is headquartered in Toronto, Canada.
PMN At a Glance
ProMIS Neurosciences, Inc.
1920 Yonge Street
Toronto, Ontario M4S 3E2
| Phone | 1-416-847-6898 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -39,719,147.00 | |
| Sector | Health Technology | Employees | 11 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PMN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.145 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
PMN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -3,610,831.545 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
PMN Liquidity
| Current Ratio | 0.879 |
| Quick Ratio | 0.879 |
| Cash Ratio | 0.591 |
PMN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -282.76 |
| Return on Equity | -521.605 |
| Return on Total Capital | 3,155.84 |
| Return on Invested Capital | -521.605 |
PMN Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |